References
- FungAERosenfeldPJReichelEThe International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBr J Ophthalmol200690111344134916854824
- RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
- LadasIDKaragiannisDARouvasAAKotsolisAILiotsouAVergadosISafety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injectionsRetina200929331331819287287
- TolentinoMSystemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular diseaseSurv Ophthalmol20115629511321335144
- AroraSMcKibbinMOne-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degenerationEye (Lond)20112581034103821597485
- LommatzschAHeimesBGutfleischMSpitalGZeimerMPauleikhoffDSerous pigment epithelial detachment in age-related macular degeneration: comparison of different treatmentsEye (Lond)200923122163216819197318
- AbouammohMSharmaSRanibizumab versus bevacizumab for the treatment of neovascular age-related macular degenerationCurr Opin Ophthalmol201122315215821483262
- MartinDFMaguireMGYingGSCATT Research Group, Ranibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
- KayCNTarantolaRMGehrsKMUveitis following intravitreal bevacizumab: a non-infectious clusterOphthalmic Surg Lasers Imaging201142429229621800802
- RajaMSGoldsmithCBurtonBJIntraocular inflammation with intravitreal bevacizumab (Avastin)Br J Ophthalmol2010944525 author reply 52520424217
- MoorthyRSValluriSJampolLMDrug-induced uveitisSurv Ophthalmol19984265575709635904
- MartelNLeeJWellsPSRisk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysisBlood200510682710271515985543
- LenzHJManagement and preparedness for infusion and hypersensitivity reactionsOncologist200712560160917522249
- GeorgopoulosMPolakKPragerFPrünteCSchmidt-ErfurthUCharacteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)Br J Ophthalmol200993445746219033289